Antibiotic Resistance
Antibiotic resistance is becoming a global crisis, leading to significant health risks and a tremendous societal economic burden.
In high-income countries, chronic urinary tract infections (UTIs) and wound infections caused by E. coli, Staphylococcus Aureus and Pseudomonas are increasingly challenging to treat, contributing to over 100,000 deaths annually in Europe and the US. The reduced efficacy of current antibiotics highlights the urgent need for new treatments that do not exacerbate resistance.
According to estimates by The Lancet, 40 million people are at risk of dying due to antibiotic resistance worldwide by 2050 if this silent pandemic is not adressed properly.

Inicure has developed patent-protected compounds acting as potent agonists of the formyl peptide receptor-1 (FPR1).
Initially developed for anti-inflammatory purposes, our compounds show potent anti-infective effects in preclinical infection models, including E. coli UTIs and Multi Resistant Staphylococcus Aureus (MRSA) infections, without causing toxicity.
Our lead candidates offer significant advantages over similar solutions, demonstrating single nM potency, and superior pharmacological properties. The compounds boost the body’s natural immune response to treat infections. Since they do not directly target the bacteria, the risk of resistance development is minimal. Instead, we see great synergistic potential for Inicure’s compounds, combined with suboptimal antibiotics.